References
- Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths — United States, 2013–2017. MMWR. 2019;67:1419–1427.
- Lyden J, Binswanger I. The United States opioid epidemic. Semin Perinatol. 2019;43(3):123–131.
- Anwar M, Law R, Schier J. Notes from the field: Kratom (Mitragyna speciosa) exposures reported to poison centers – United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(29):748–749.
- Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to United States poison control centers: 2011–2017. Clin Toxicol. 2019;57(10):847–854.
- Cinosi E, Martinotti G, Simonato P, Singh D, et al. Following “the roots” of kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in western countries. Biomed Res Int. 2015;2015:968711–968786.
- Schimmel J, Amioka E, Rockhill K, et al. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross‐sectional study. Addiction. 2021;116(1):176–181.
- Coe M, Pillitteri J, Sembower M, Gerlach K, Henningfield J. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. 2019;202:24–32.
- Stanciu C, Gnanasegaram S, Ahmed A, Penders T. Kratom withdrawal: a systematic review with case series. J Psychoactive Drugs. 2019;51(1):12–18.
- Kruegel A, Gassaway M, Kapoor A, et al. Synthetic and receptor signaling explorations of the Mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016;138(21):6754–6764.
- Chien G, Odonkor C, Amorapanth P. Is kratom the new ‘legal high’on the block?: The case of an emerging opioid receptor agonist with substance abuse potential. Pain Physician. 2017;20:E195–E198.
- Eastlack S, Cornett E, Kaye A. Kratom-pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther. 2020;9(1):55–69.
- Khazaeli A, Jerry J, Vazirian M. Treatment of kratom withdrawal and addiction with buprenorphine. J Addict Med. 2018;12(6):493–495.
- Singh D, Müller C, Vicknasingam B. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132–137.
- Abdullah B, Leong M. Kratom dependence and treatment options: a comprehensive review of the literature. Current Drug Targets. 2020;21(15):1566–1579.
- Buresh M. Treatment of kratom dependence with buprenorphine-naloxone maintenance. J Addict Med. 2018;12(6):481–483.
- Weiss S, Douglas H. Treatment of kratom withdrawal and dependence with bupreorphine/naloxone: a case series and systematic literature review. Journal of Addiction Medicine. 2021;15(2):167–172.
- Bowe A, Kerr P. A complex case of kratom dependence, depression, and chronic pain in opioid use disorder: effects of buprenorphine in clinical management. J Psychoactive Drugs. 2020;52 (5):447–452.
- Kalin S, Dakhlalla S, Bhardwaj S. Treatment for kratom abuse in a contingency-management-based MAT setting: a case series. J Opioid Manage. 2020;16(5):391–394.
- Lei J, Butz A, Valentino N. Management of kratom dependence with buprenorphine/naloxone in a veteran population. Substance Abuse. 2021;42:1–11.